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Abstract  
Purpose: This pre-trial qualitative research study was carried out to explore patient and clinical staff 
attitudes to central venous access devices (CVADs). In addition, views about participation in a 
randomised controlled trial (RCT) were explored with the aim of maximising recruitment to an 
imminent RCT of three CVADs.  
Methods: Three patient focus groups (each comprising three patients) and 23 interviews with clinical 
staff were conducted. Interviews and focus group discussions were digitally recorded, transcribed 
verbatim, anonymised, uploaded to the QSR NVivo10 qualitative software programme and 
thematically analysed.  
Results: Analysis of focus group interviews revealed the added challenges that a CVAD poses to 
patients with cancer. Four key themes emerged: continuity of daily life, pain and discomfort, stigma 
(a mark of disgrace associated with certain conditions) and self-preservation. The findings show the 
impact of a CVAD on patients’ ability to manage their condition. Clinical staff interviews highlighted 
several potential barriers to recruitment; a lack of equipoise (genuine clinical uncertainty as to which 
intervention is the most beneficial), concerns about the logistics of device insertion and a perceived 
requirement for education and training.  
Conclusions: This qualitative study raises awareness of key areas of concern to patients who need a 
CVAD for chemotherapy delivery. It was identified that there is a need for clearer patient 
information around CVADs. Additionally it allows investigators to identify barriers to recruitment in a 
timely manner in order to minimise the potential for conflict between the roles of carer and 
researcher and consequently, maximise recruitment to the RCT.  
Keywords: Cancer, Health professionals’ attitudes, Patient attitudes, Qualitative research, 
Randomised controlled trials, Venous access devices.  
 
Background  
This paper presents the results of a nested pre-trial qualitative research study carried out to inform a 
randomised controlled trial (RCT) of central venous access devices (CVADs).  
Qualitative and quantitative research are the two main research paradigms; whilst quantitative 
research tends to use numerical data, qualitative research uses language data either in the written 
or oral form (1). The value of utilising a mixture of quantitative and qualitative methods in 
developing and evaluating complex interventions is highlighted in recent Medical Research Council 
Guidance (2) and funders increasingly expect to see a qualitative research component incorporated 
in a study design. A nested qualitative study in a larger RCT serves to provide in-depth, explanatory 
information to inform the main trial, provide additional explanatory information on the findings and 
to incorporate patient and service user involvement in the research.  
A systematic review and meta-analysis evaluating the risks of complications associated with centrally 
inserted external catheters compared with totally implantable Ports in patients undergoing 
chemotherapy showed that totally implantable Ports are superior to external catheters in terms of 
catheter-associated complications (3). The National Institute for Health Research Health Technology 
Assessment Programme has commissioned the Cancer and Venous Access (CAVA) study (4), the first 
RCT to compare the clinical and cost-effectiveness of three venous access devices for chemotherapy 
delivery; tunnelled-cuffed central catheters, peripherally inserted central catheters (PICCs) and 
implantable chest wall Ports (Ports). The CAVA study opened to recruitment in November 2013. Each 
eligible patient will have four randomisation options: tunnelled-cuffed central catheters versus PICC 
versus Port, PICC versus Port, PICC versus tunnelled-cuffed central catheters or tunnelled-cuffed 
central catheters versus Port. The study aims to recruit 2,000 patients over 36 months from six UK 
centres.  
The difficulties associated with recruitment, especially in multi-centre trials, have been well 
documented (5). A recent cohort study of 114 multicentre trials found that less than a third achieved 
their original target and more than half had to be extended (6). In recent years, qualitative research 
methods have been shown to be successful in increasing rates of randomisation in RCTs (7). To be 
effective and in particular to allow adequate time for the implementation of findings, qualitative 
research needs to be undertaken at the feasibility stage of a trial, or fully integrated into the design 
of the RCT (8, 9). Consequently, this qualitative research study was informed by a feasibility study 
(10) and incorporated into the design of the Phase III study from conception. This pre-trial 
qualitative research explores patient and clinical staff attitudes to the three CVADs and attitudes to 
participation in an RCT of CVADs in order to provide tailored strategies to aid recruitment to the 
CAVA study. The results of this qualitative research have been presented using the approach 
recommended for reporting a qualitative study, including selected verbatim quotations, which 
clearly illustrate particular points and which provide support for the findings (11).  
 
Methods  
A literature search was undertaken of the CINAHL database to include Medline, PsychInfo, Soc Index, 
Embase and PubMed. The search covered two main areas of research: firstly, patient and clinical 
staff attitudes to RCTs and secondly, patient and clinical staff attitudes to venous access devices.  
Many qualitative studies have explored the views of cancer patients to the process of RCTs, 
exploring informed consent (12, 13), understanding of equipoise (14), randomisation (15), 
recruitment (13, 14, 16) and participation in trial design (17). Despite this, recent research reveals 
health professionals’ discomfort at approaching patients to discuss participation in an RCT at an 
already stressful period for the patient (17). In addition, whilst several qualitative studies examine 
patient experiences of a single device (18-23), few examine patients’ attitudes to device choice; 
those which do, focus on educational and information needs in relation to device selection (24, 25). 
There is little in the literature to describe health professionals’ attitudes to choice of venous access 
devices. Quantitative studies indicate that whilst factors such as cost, durability and ease of use for 
medical personnel all feature in device decision making, little or no consideration is given to 
participants’ views or preferences (26, 27). The need for more studies to investigate the issue of 
patient satisfaction and quality of life in relation to venous access devices has been highlighted (28).  
The pre-trial study was carried out in the 9 months prior to recruitment. The study comprised two 
components: three focus groups with three patients in each and 23 interviews with clinical staff.  
 
Focus groups  
Following ethical and Research and Development (R&D) management approval of the study, patients 
were approached in chemotherapy clinics and day care units and invited to participate in the study. 
A patient information leaflet was sent out by post or handed out to interested patients. The 
researcher followed up the initial contact with a telephone call to discuss any queries and to recruit 
participants. Patients were sampled purposively to include newly diagnosed as well as metastatic 
tumours and both solid and haematological malignancies, with the aim also to get a reasonable 
balance between women and men. Initial plans to hold one focus group of ten patients were 
modified when recruitment proved more difficult than anticipated. Barriers to focus group 
recruitment included ill-health, treatment schedules, travel issues, work commitments and a 
reluctance to join in a group discussion. Therefore, following consultation with the CAVA project 
management group, the decision was taken to recruit three separate focus groups. A total of nine 
patients receiving treatment for cancer at the lead centre (Beatson West of Scotland Cancer Centre 
(BWoSCC), Glasgow) took part in three separate focus groups of three participants each. Four males 
and five females participated. Participants’ ages ranged from 48 to 66 years. All participants had 
solid tumours, including two with metastatic disease. Three had experience of an implanted Port, 
three of a PICC line and two of a tunnelled-cuffed central catheter. One had experience of both a 
PICC and a tunnelled-cuffed central catheter. Four participants had previously participated in an RCT. 
The focus group discussions took place in a private room and were facilitated by the researcher 
accompanied by an assistant. Signed consent to participation and to audio recording of the 
discussion was obtained. The focus group discussion followed a prepared schedule encompassing 
questions on participants’ attitudes, experience and preferences relating to the three devices and on 
participants’ understanding of the study design and willingness to participate in a randomised trial of 
the three devices. Aids included demonstration devices, laminated photographs of the devices in situ 
and copies of the patient information sheet for the trial. Each group discussion lasted around 1 hour. 
All focus group discussions were digitally recorded. Recordings were transcribed verbatim, 
anonymised, uploaded to the QSR Nvivo10 software programme and thematically analysed by the 
researcher.  
 
Clinical Staff Interviews  
Following ethical approval for the study and R&D management approval at each centre, clinical staff 
were contacted by email by the researcher and invited to participate in the interviews. A participant 
information sheet was emailed to the Principal Investigator and relevant members of staff at each 
centre and the initial contact was followed up to ascertain agreement to participation. Twenty three 
clinical staff (oncologists (4), radiologists (6), haematologists (3), anaesthetists (1) and nurses (9)) 
from across the six centres were recruited as it was anticipated that there would be variations in 
attitudes regarding equipoise across specialities and differences in local practice which might affect 
recruitment. The researcher visited each of the participating centre to interview staff. Written 
consent to participation and to audio recording of the interview was obtained prior to each 
interview. A prepared schedule was followed encompassing perceived barriers and facilitators to 
recruitment and attitudes to the three devices and to RCTs. Feedback was obtained on trial 
materials including patient information sheets and consent forms. Clinical staff interviews were 
digitally recorded. Recordings were transcribed verbatim, anonymised, uploaded to the QSR Nvivo10 
qualitative software programme and thematically analysed by the researcher.  
 
Results  
Focus Groups  
The focus group discussions generated a number of themes. These were continuity of daily life, pain 
and discomfort, stigma (a mark of disgrace associated with certain conditions) and self-preservation. 
These issues, whilst common within the experience of those suffering from cancer (29-33), appear to 
be magnified by the presence of a vascular access device. The key themes will be explored in turn 
below.  
 
Continuity of daily life  
The need to retain continuity of daily life emerged as a priority. Comments indicate that patients are 
motivated to adapt to the presence of the device and to focus on strategies to minimise disruption 
to their daily activities.  
 
‘.. it (was) really very, very simple, just sort of put the sleeve on and pop into your bath and you kept 
it sort of like... water free, it was good.’ [Female, 48, Breast cancer, PICC]  
 
Although discussions revealed that the Port could be seen to confer ‘pure freedom’ (a colloquial 
term conveying a high level of freedom), fatigue and other factors, including wound care, pain or 
complications with the venous access device, could limit activities and negate the perceived benefits 
of a totally implanted device.  
 
‘...but with an open wound on my back I couldn’t go swimming anyway so, you know, I couldn’t really 
see the benefits of the others.’ [Female, 48, Breast cancer, PICC]  
 
Conversely, the need for additional line care and maintenance in the case of the PICC and tunnelled-
cuffed central catheter can lead to an undesirable dependency on health care professionals.  
‘You just feel as if your life’s on hold.’ [Male, 59, Metastatic colon cancer, PICC]  
 
Pain and discomfort  
A further burden for the patient is the fact that the vascular access device can be the cause of 
significant additional pain and discomfort: whether at the time of insertion and removal, due to 
complications or due to device malfunction necessitating alternative venipuncture. In addition, 
participants reported having underestimated the extent of the procedure (Port) and finding the 
process impersonal (tunnelled-cuffed central catheter). Insertion of the PICC line attracted the least 
comment.  
 
‘I don’t think I appreciated the procedure of when it was put in, that how, you know, they would be 




Despite adapting to the practicalities of having a device in situ, the desire to hide the device 
emerged as a strong theme in discussions. Participants emphasised this point, using the words 
‘conceal’, hide and ‘cover’ repeatedly.  
 
‘And as we said; you can cover it. It’s not that you’re embarrassed but it’s likes of children come into 
the house...or grandchildren...or people that don’t know anything about your disease or your 
sickness...and there might be something sticking out somewhere. No, no, no, no, no, no. I’ll try and 
hide it as much as I can, you know.’ [Male, 66, Metastatic colon cancer, PICC]  
 
Whilst the Port is the most satisfactory in this regard, being almost undetectable, participants 
describe being able to successfully mask the other two devices with careful attention to the 
selection of appropriate clothing.  
 
Self-preservation  
Patients view the device as a ‘necessary evil’ and feel compelled to assume a defensive stance in 
relation to its care and maintenance, in extreme cases undertaking self-care.  
 
‘It’s self-preservation and I have been quite happy to say to people ehm, ‘excuse me, you don’t know 
what you’re doing, eh, don’t touch my Hickman line.’ [Female, 56, Breast cancer, Tunnelled-cuffed 
central catheter]  
 
This theme of self-preservation can also be seen in the desire to retain some degree of control of 
aspects of care and treatment where possible, including control over choice of device.  
 
‘So personally, eh, if the computer choose me to have the PICC line, I would agree, but if they choose 
something else, I’m sorry to say I would like to know the computer’s name, because I would disagree 
with him.’ [Male, 66, Metastatic colon cancer, PICC]  
 
A further protective mechanism is revealed in the need to avoid acknowledgement of the severity of 
the illness. In some instances patients appear reluctant to accept the need for an invasive procedure 
or obtrusive device in order to deliver treatment.  
 
‘I felt that (having) a Hickman, you know, having lost your hair (and) everything else, just gave you 
this vision of being very, very sick, when I didn’t actually feel that sick.’ [Female, 48, Breast cancer, 
PICC]  
 
Clinical staff interviews  
Three key themes emerged from clinical staff interviews. Firstly, a lack of equipoise in relation to the 
devices; secondly, the challenges of introducing or expanding a Port insertion service and thirdly, the 
need for extensive and comprehensive training in the care and maintenance of unfamiliar devices, 
mainly Ports.  
 
Lack of equipoise (genuine clinical uncertainty as to which intervention is the most beneficial)  
Equipoise provides the ethical basis for an RCT. Interviews with clinical staff revealed device 
preferences for certain subgroups of patients. As a result, only one centre will consider haematology 
patients for randomisations including Ports. In other centres haematologists expressed reservations 
regarding Ports and/or PICC lines or have yet to engage in the study.  
 
‘We are actually not familiar with (the Port) in adult Haematology or Oncology really I mean...it 
would be a major practical problem to be inserting it into our Haematology patients in terms of the 
insertion itself, there is a possibility that the bleeding risk and the infection risk could create more 
problems for my type of patients, because these are acute leukaemia patients….’ [Haematologist, 
Leeds]  
 
Logistics of Port insertion appointments  
Secondly the introduction or expansion of a Port insertion service will inevitably create challenges, 
including training additional Port inserters, making sufficient Port insertion slots available, providing 
a service for Port removal and, in two centres, acquiring funding for Ports. Furthermore, the element 
of randomisation between devices has the potential to create an additional level of complexity in the 
process of commencing a patient on chemotherapy.  
 
‘I think that patient nurse specialists and the outpatient nurses in the Sarcoma practice and the 
young peoples’ practice are dealing with a complex sequence of events around getting a patient 
started on chemotherapy and they will vary in their gratitude for a further complexity to be 
introduced.’ [Oncologist, Leeds]  
 
This is particularly relevant in Oncology and Haematology where the time from referral for line 
insertion to treatment can be short and any perceived potential delays to chemotherapy delivery 
will impact negatively on patient recruitment.  
 
‘I think, obviously you know kind of access to Interventional Radiology might be the decider here 
because if there is a waiting list to put a Port in, what have you, then your treatment targets have to 
be met either for cancer waiting time target or from a clinical need target type of thing.’ [Oncologist, 
Newcastle]  
 
The introduction of Ports for chemotherapy delivery also creates a requirement for Port removal 
appointments, in many centres this is in addition to current workload and therefore raises the issue 
of additional service provision. Responses to this varied across centres with the onus falling variously 
on surgical, radiology or anaesthetic departments to meet this new demand.  
 
Lack of experience and training  
Finally, an increase in the number of Ports in use for chemotherapy delivery has ramifications for 
ward and primary care staff involved in the care and maintenance of Ports, therefore training and 
education is a key issue in all centres. In some centres experience of Ports for chemotherapy delivery 
is limited and the need for additional training is apparent. The qualitative research interviews in 
Glasgow, drawing on experiences from the feasibility study, highlighted a lack of confidence and 
experience with Ports as a major concern. Despite a programme of training, the learning curve 
generated by the new device resulted in additional referrals to Interventional Radiology for 
assistance with maintenance issues and additional hospital visits by patients for procedures normally 
carried out by the Primary Care team.  
 
‘…as a nurse-led team we know the ramifications of the management within the hospital of new 
devices, and in the community. Little changes for us have massive ramifications for other areas…’ 
[Procedure Team Manager, Manchester]  
 
However, the qualitative research interviews did highlight the nursing staff’s enthusiasm and 
commitment to developing the necessary skills.  
 
‘So that’s a big buzz, eh, you know when we problem solve in a successful way. And I know that once 
we get used to Ports, we’ll love them.’ [Oncology Nurse, Glasgow]  
 
Discussion  
The presence of the venous access device challenges the patient’s ability to manage their condition 
in several respects. The themes identified, continuity of daily life, pain and discomfort, stigma and 
self-preservation, whilst common within the experience of those suffering from cancer (29-33), 
appear to be magnified by the presence of a vascular access device. The need to avoid disruption to 
daily life in order to cope with chronic illness is well documented (29). Focus group discussions 
reveal that the device has the potential to impact significantly on this, requiring increased 
intervention by health care professionals. In addition, the potential for the device to add to the 
patient’s level of pain and discomfort cannot be ignored. A significant degree of pain and discomfort 
was reported by some patients at the stage of insertion of the device. A particular consideration for 
recruiters to CAVA is the fact that participants may be randomised to any of the three devices and 
therefore need to be fully aware of insertion procedure for each device as well as the impact of the 
pre- and post-insertion period. A further concern to patients is the fear of stigma. It is recognised 
that stigma (or a mark of disgrace associated with certain conditions) is a central force in the lives of 
those with cancer (32). Focus group discussions reveal that the device represents an undesirable 
visible indicator of the disease and it may be concluded that the fear of stigma leads patients to 
want to conceal the device. Unlike chemotherapy-induced alopecia (33), patients with a venous 
access device in situ can, and often do, choose to keep the presence of the device concealed from 
others and become adept at developing strategies to hide the device. Similarly, whilst patients 
recognise the catheter’s central role in delivering treatment and hopefully a cure, they constantly 
fear complications (30). Thus the device is seen as both a lifesaving mechanism and a threat. Self-
preservation takes many guises; from undertaking self-care of the device to the need to retain 
control of choice of device or treatment schedules. Patients therefore may be reluctant to 
participate in an RCT due to a desire to be actively involved in decision-making (34, 35). A further 
example of self-preservation is avoiding confrontation with the seriousness of the disease, a process 
recognised as cancer-specific denial and accepted as a recognised coping strategy in cancer patients 
(31). Cancer-specific denial may be a subtle influence in the preference for a less invasive or 
obtrusive device and consequently in the decision whether or not to enter a randomised study of 
venous access devices. 
A review of relevant qualitative research has identified patient preference for one particular 
treatment arm as a major barrier to recruitment (9). A corresponding tendency by health 
professionals to accord with patient preferences, where they coincide with recruiters’ own views, 
has also been highlighted in the literature (36). The benefit of being able to elicit and address patient 
preferences has been recognised and in this way recruiters may be able to gently challenge patients’ 
preconceptions, as well as recognising and acknowledging their own bias in device preference. The 
findings from the pre-trial qualitative study reported here will allow CAVA recruiters to be alert to 
patients expressing concerns with regard to continuity of daily life, stigma, fear of pain and 
discomfort and above all self-preservation. Furthermore, the need to avoid confrontation with the 
seriousness of the disease or a need to retain control of device choice or ultimately whether or not 
to have a device in situ will impact on the decision to enter an RCT.  
The analysis of pre-trial clinical staff interviews identified both local issues and themes common 
across centres. The main themes, lack of equipoise, logistics of service delivery and the need for 
education and training, could potentially present significant barriers to recruitment.  
Current literature indicates that more subtle influences may prevail in the process of recruitment 
and clinicians and nurses’ own attitudes and preferences whilst not immediately apparent, 
unconsciously affect recruitment (36). Recent studies reveal that, despite being strongly committed 
to the RCT, recruiters exhibited discomfort at the process of recruitment, occasionally openly but 
often covertly, displaying conflict between the roles of carer and researcher and demonstrating 
selectiveness in the choice of patients to approach (36). Therefore identifying and addressing issues 
likely to contribute to this conflict is of fundamental importance in maximising recruitment.  
Services at each centre vary significantly and there is acknowledgement that there may be 
competing demands for slots for Port insertion in some centres. In others, Port insertion for 
chemotherapy is in addition to existing workload. Here the danger is that recruiters’ own 
perceptions of organisational difficulties reinforce those of patients (36). As a result of the pre-trial 
qualitative research findings, the remit of the funded role of CAVA Champion (a dedicated member 
of the study team at each centre) has been developed to encompass not only recruitment and 
randomisation but also coordination and facilitation of device insertion appointments, 
communication and liaison across specialities and education and dissemination of knowledge.  
The need for additional staff training, particularly in the use of Ports, will impact on recruitment 
initially, limiting randomisation for haematology patients to the two-way randomisation between 
PICCs and tunnelled-cuffed central catheters in some centres. Several approaches have been taken 
to address the need for training; details of effective training models and mannequins, sourced 
through Industry, have been shared between centres. In addition, nurses with experience of Ports 
will cascade the knowledge to other staff within individual centres. Notification of national training 
courses in device insertion, care and maintenance has been made to Principal Investigators at the 
launch meeting.  
Despite some evidence of a lack of equipoise on the part of haematologists, there is an emerging 
opinion amongst some haematologists that this is an important question in this particular group of 
patients and there is optimism that there may be further engagement by haematologists across the 
period of recruitment.  
This qualitative research is one of only a few fully integrated, qualitative research studies in large 
multi-centre RCTs. This integration has allowed the analysis, feedback and interventions to take 
place prior to the study opening to recruitment.  
 
Conclusion  
This pre-trial qualitative study raises awareness of key areas of concern to patients who need a 
venous access device for chemotherapy delivery. The findings show the potential for a venous access 
device to magnify existing difficulties, posing additional challenges to patients’ ability to manage 
their condition. From the findings it was identified that there is a need for clearer patient 
information, education and training around CVADs.  
Following presentation of the pre-trial qualitative research analysis Principal Investigators and CAVA 
Champions at each centre are able to recognise issues likely to adversely impact on recruitment 
including lack of equipoise in certain patient subgroups, potential logistical obstacles to device 
insertion appointments and the need for additional education and training in Port care and 
maintenance. As a result, investigators are able to consider and address potential difficulties in a 
timely manner, thus minimising the potential for conflict between the roles of carer and researcher 
identified in recent literature (36) and ultimately maximising recruitment to the CAVA trial.  
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